Cancer treatment-related neuropathic pain syndromes—epidemiology and treatment: An update

Current Pain and Headache Reports

Volumn 18, Issue 11, 2014, Pages 1-10

  Smith, Ellen M Lavoie ^a   Bridges, Celia M ^a   Kanzawa, Grace ^a   Knoerl, Robert ^a   Kelly, James P ^b   Berezovsky, Anna ^b   Woo, Charis ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF NURSING   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cancer treatment related pain; Chronic pain; Neuropathic pain

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CALCIUM CHANNEL ALPHA2 D LIGAND ANTICONVULSANT; CAPSAICIN; DULOXETINE; LEVOBUPIVACAINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CHRONIC PAIN; EPIDEMIOLOGICAL DATA; HUMAN; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); CENTRAL NERVOUS SYSTEM; COMPLICATION; DRUG EFFECTS; NEOPLASMS; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM; PSYCHOLOGY; RADIATION INJURIES; RADIATION RESPONSE; SURVIVOR;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM; HUMANS; NEOPLASMS; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM; QUALITY OF LIFE; RADIATION INJURIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVORS;

EID: 84948774445     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-014-0459-7     Document Type: Article

References (100)

1. American Cancer Society. Cancer facts and figures 2014. American Cancer Society Cancer Facts and Figures 2014 Web site. Available at: http://www.cancer.org/acs/groups/content/@ research/documents/webcontent/acspc-042151.pdf. Published 2014. Updated 2014. Accessed March 26, 2014.
2. Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30:1980–8.
3. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–49.
4. Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Investig. 2005;23:182–90.
5. Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012;153:359–65. A systematic review of 22 eligible studies that included a total of 13,683 patients with cancer to determine NP prevalence.
6. Rayment C, Hjermstad MJ, Aass N, et al. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European palliative care research collaborative-computerised symptom assessment study. Palliat Med. 2013;27:714–21.
7. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14:79–94.
8. International Association for the Study of Pain (IASP). Pain terminology. Available at: http://www.iasp-pain.org/AM/Template.cfm?Section=General_Resource:Links&Template=/CM/HTMLDisplay.cfm&ContentID=3058#Pain. Updated 2008. Accessed June 24, 2014.
9. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–19. Provides a comprehensive description of neuropathic pain mechanisms and treatment with informative illustrations.
10. Tracey I, Bushnell MC. How neuroimaging studies have challenged us to rethink: is chronic pain a disease? J Pain. 2009;10: 1113–20.
11. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Sup):S2–S15.
12. Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W. Idiopathic pain disorders—pathways of vulnerability. Pain. 2006;123:226–30.
13. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways thatmodulate pain. J Clin Neurophysiol. 1997;14: 2–31.
14. Miaskowski C, Paul SM, Cooper B, et al. Identification of patient subgroups and risk factors for persistent arm/ shoulder pain following breast cancer surgery. Eur J Oncol Nurs. 2014;18:242–53.
15. Bruce J, Thornton AJ, Powell R, et al. Psychological, surgical, and sociodemographic predictors of pain outcomes after breast cancer surgery: a population-based cohort study. Pain. 2014;155:232–43. An important prospective cohort study identifying key predictors of chronic NP following breast cancer treatment.
16. Brummett CM. Chronic pain following breast surgery. Tech Reg Anesth Pain Manag. 2011;15:124–32.
17. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302:1985–92.
18. Hinrichs-Rocker A, Schulz K, Jarvinen I, Lefering R, Simanski C, Neugebauer EA. Psychosocial predictors and correlates for chronic post-surgical pain (CPSP) - a systematic review. Eur J Pain. 2009;13:719–30.
19. Lundstedt D, Gustafsson M, Malmström P, et al. Symptoms 10–17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiother Oncol. 2010;97:281–7.
20. Johansson S, Svensson H, Larsson LG, Denekamp J. Brachial plexopathy after postoperative radiotherapy of breast cancer patients—a long-term follow-up. Acta Oncol. 2000;39:373–82.
21. Chen PY, Wallace M, Mitchell C, et al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:991–7.
22. Manas A, Monroy JL, Ramos AA, et al. Prevalence of neuropathic pain in radiotherapy oncology units. Int J Radiat Oncol Biol Phys. 2011;81:511–20.
23. Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol. 2009;93:408–13.
24. Nissenbaum J, Devor M, Seltzer Z, et al. Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Res. 2010;20:1180–90.
25. Sheridan D, Foo I, O'Shea H, et al. Long-term follow-up of pain and emotional characteristics of women after surgery for breast cancer. J Pain Symptom Manag. 2012;44:608–14.
26. Pielsticker A, Haag G, Zaudig M, Lautenbacher S. Impairment of pain inhibition in chronic tension-type headache. Pain. 2005;118: 215–23.
27. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114:295–302.
28. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997;70:41–51.
29. Yarnitsky D, Crispel Y, Eisenberg E, et al. Prediction of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. Pain. 2008;138:22.
30. Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. Curr Opin Anaesthesiol. 2010;23:611–5.
31. Weissman-Fogel I, Granovsky Y, Crispel Y, et al. Enhanced presurgical pain temporal summation response predicts postthoracotomy pain intensity during the acute postoperative phase. J Pain. 2009;10:628–36.
32. Edwards RR, Ness TJ, Weigent DA, Fillingim RB. Individual differences in diffuse noxious inhibitory controls (DNIC): association with clinical variables. Pain. 2003;106:427–37.
33. Campbell CM, Edwards RR. Mind-body interactions in pain: the neurophysiology of anxious and catastrophic pain-related thoughts. Transl Res J Labor Clin Med. 2009;153:97–101.
34. Edwards RR, Calahan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol. 2011;7:216–24.
35. Edwards RR, Bingham III CO, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 2006;55:325–32.
36. Sullivan MJ, Thorn B, Haythornthwaite JA, et al. Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain. 2001;17:52–64.
37. Pavlin DJ, Sullivan MJ, Freund PR, Roesen K. Catastrophizing: a risk factor for postsurgical pain. Clin J Pain. 2005;21:83–90.
38. Jacobsen PB, Butler RW. Relation of cognitive coping and catastrophizing to acute pain and analgesic use following breast cancer surgery. J Behav Med. 1996;19:17–29.
39. Theunissen M, Peters ML, Bruce J, Gramke HF, Marcus MA. Preoperative anxiety and catastrophizing: a systematic review and meta-analysis of the association with chronic postsurgical pain. Clin J Pain. 2012;9:819–41.
40. Masselin-Dubois A, Attal N, Fletcher D, et al. Are psychological predictors of chronic postsurgical pain dependent on the surgical model? A comparison of total knee arthroplasty and breast surgery for cancer. J Pain. 2013;14:854–64.
41. Turner JA, Jensen MP, Romano JM. Do beliefs, coping, and catastrophizing independently predict functioning in patients with chronic pain? Pain. 2000;85:115–25.
42. Crisson JE, Keefe FJ. The relationship of locus of control to pain coping strategies and psychological distress in chronic pain patients. Pain. 1988;35:147–54.
43. Strong J, Cramond T. Pain intensity, attitude and function in back pain patients. Pain. 1990;41:S499.
44. Powell R, Johnston M, Smith WC, et al. Psychological risk factors for chronic post-surgical pain after inguinal hernia repair surgery: a prospective cohort study. Eur J Pain. 2012;16:600–10.
45. Raphael KG, Widom CS. Post-traumatic stress disordermoderates the relation between documented childhood victimization and pain 30 years later. Pain. 2011;152:163–9.
46. Humphreys J, Cooper BA, Miaskowski C. Differences in depression, posttraumatic stress disorder, and lifetime trauma exposure in formerly abused women with mild vs moderate to severe chronic pain. J Interpers Violence. 2010;25:2316–38.
47. Barry DT, Beitel M, Cutter CJ, et al. Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients. J Pain. 2011;12:22–8.
48. Baccini F, Pallotta N, Calabrese E, Pezzotti P, Corazziari E. Prevalence of sexual and physical abuse and its relationship with symptom manifestations in patients with chronic organic and functional gastrointestinal disorders. Dig Liver Dis. 2003;35: 256–61.
49. Meltzer-Brody S, Leserman J, Zolnoun D, Steege J, Green E, Teich A. Trauma and posttraumatic stress disorder in women with chronic pelvic pain. Obstet Gynecol. 2007;109:902–8.
50. Golding JM. Sexual assault history and headache: five general population studies. J Nerv Ment Dis. 1999;187:624–9.
51. Campbell JC, Lewandowski LA. Mental and physical health effects of intimate partner violence on women and children. Psychiatr Clin N Am. 1997;20:353–74.
52. Coker AL, Smith PH, Bethea L, King MR, McKeown RE. Physical health consequences of physical and psychological intimate partner violence. Arch Fam Med. 2000;9:451–7.
53. Ducic I, Zakaria HM, Felder JM, Fantus S. Nerve injuries in aesthetic breast surgery: systematic review and treatment options. Aesthet Surg J. 2014.
54. Poleshuck EL, Katz J, Andrus CH, et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain. 2006;7:626–34.
55. Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain. 2011;12:725–46. A systematic review of 60 studies describing predictors of chronic pain after breast cancer.
56. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008;99:604–10.
57. Gahm J, Wickman M, Brandberg Y. Bilateral prophylactic mastectomy in women with inherited risk of breast cancer—prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast. 2010;19: 462–9.
58. Bayman EO, Brennan TJ. Incidence and severity of chronic pain at 3 and 6 months after thoracotomy: meta-analyses. J Pain. 2014;15(9):887–897. A rigorously conducted systematic review/ meta-analysis of 22 studies to assess the incidence and severity of chronic pain at 3 and 6 months after thoracotomy.
59. Hill A. Phantom limb pain: a review of the literature on attributes and potential mechanisms. J Pain SymptomManag. 1999;17:125–42.
60. Prantl L, Schreml S, Heine N, Eisenmann-Klein M, Angele P. Surgical treatment of chronic phantom limb sensation and limb pain after lower limb amputation. Plast Reconstr Surg. 2006;118: 1562–72.
61. van Wilgen CP, Dijkstra PU, van der Laan BF, Plukker JT, Roodenburg JL.Morbidity of the neck after head and neck cancer therapy. Head Neck. 2004;26:785–91.
62. Polomano RC, Farrar JT. Pain and neuropathy in cancer survivors. Cancer Nurs. 2006;29:39.
63. Pignol JP, Olivotto I, Rakovitch E, et al.Amulticenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085–92.
64. Vicini FA, Chen P, Wallace M, et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2007;69:1124–30.
65. Inomata T, Narabayashi I, Inada Y, et al. Patients’ subjective evaluation of early and late sequelae in patients with breast cancer irradiated with short fractionation for breast conservation therapy: comparison with conventional fractionation. Breast Cancer. 2008;15:93–100.
66. Dodd MJ, Cho MH, Cooper BA, Miaskowski C. The effect of symptom clusters on functional status and quality of life in women with breast cancer. Eur J Oncol Nurs. 2010;14:101–10.
67. Ebbeskov Lauritsen L, Meidahl Petersen P, Daugaard G. Neurological adverse effects after radiation therapy for stage II seminoma. Case Rep Oncol. 2012;5:444–8.
68. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dosevolume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010;76(3 Sup):S42–9.
69. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49.
70. Kautio AL, Haanpaa M, Kautiainen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy—a cross-sectional study. Support Care Cancer. 2011;19:1991–6.
71. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapyinduced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82:51–77.
72. Gutierrez-Gutierrez G, Sereno M, Miralles A, Casado-Saenz E, Gutierrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010;12:81–91.
73. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Syst. 2008;13:27–46.
74. Smith EM, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapyinduced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs. 2010;33:173–83.
75. Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29:1472–8.
76. Wampler MA, Miaskowski C, Hamel K, Byl N, Rugo H, Topp LS. The modified total neuropathy score: a clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. Support Oncol. 2006;4:W9–W16.
77. Anonymous. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. the elderly lung cancer vinorelbine Italian study group. J Natl Cancer Inst. 1999;91:66–72.
78. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. The only large RCT published to date supporting the use of an effective intervention for painful chemotherapy-induced peripheral neuropathy.
79. Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115:3631–9.
80. Smith E, Bakitas MA, Homel P, et al. Using quality improvement methodology to improve neuropathic pain screening and assessment in patients with cancer. J Cancer Educ. 2009;24:135–40.
81. Haanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14–27.
82. Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17: 1010–8.
83. Jongen JL, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symp Manag. 2013;46:581–90.e1.
84. Dworkin R, O'Connor A, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237.
85. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacologic treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–e88.
86. Moulin DE, Clark AJ, Gilron I, et al. Pharmacologic management of chronic neuropathic pain - consensus statement and guidelines from the Canadian pain society. Pain Res Manag: J Can Pain Soc. 2007;12:13.
87. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.[see comment]. [review] [70 refs]. Arch Neurol. 2003;60:1524–34.
88. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacologic management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–S14.
89. Finnerup N, Otto M, Jensen T, Sindrup S. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed. 2007;9:36.
90. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacologic treatment of neuropathic pain. Pain. 2010;150:573–81.
91. Amr YM, Yousef AA. Evaluation of efficacy of the perioperative administration of venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J Pain. 2010;26:381–5. A RCT supporting the use of an effective intervention to prevent breast cancer surgery-related NP.
92. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6:17–24.
93. Strazisar B, Besic N. Comparison of continuous local anaesthetic and systemic pain treatment after axillary lymphadenectomy in breast carcinoma patients - a prospective randomized study. Radiol Oncol. 2013;47:145–53.
94. Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain. 1998;75:349–54.
95. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebocontrolled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997;15:2974–80.
96. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996;64:293–302.
97. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014. A recently published clinical practice guideline based on a systematic review of 48 RCTS testing interventions to prevent or treat CIPN.
98. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.
99. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98: 195–203.
100. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebocontrolled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supp Care Cancer. 2011;19:833–41.